중증근무력증 치료 시장 : 치료 분류, 질환 유형, 투여 경로, 유통 채널, 최종 사용자별 예측(2026-2032년)

The Myasthenia Gravis Treatment Market is projected to grow by USD 2.71 billion at a CAGR of 7.88% by 2032.

Myasthenia gravis treatment is moving from broad immunosuppression toward targeted, biomarker-informed care for a chronic autoimmune neuromuscular disorder that causes fluctuating skeletal muscle weakness, most often involving ocular, bulbar, limb, and respiratory muscles. Standard therapies such as acetylcholinesterase inhibitors, corticosteroids, steroid-sparing immunosuppressants, thymectomy, intravenous immunoglobulin, and plasma exchange remain important, especially for acute exacerbations and generalized myasthenia gravis.

The treatment landscape is being reshaped by U.S. FDA- and EMA-reviewed biologics that address complement activation and neonatal Fc receptor pathways. Eculizumab, ravulizumab, efgartigimod, rozanolixizumab, and zilucoplan have expanded options for acetylcholine receptor antibody-positive disease and, in selected indications, broader antibody-defined populations. These advances are increasing demand for earlier diagnosis, antibody testing, specialty neurology access, payer evidence, and long-term safety monitoring.

Transformative Shifts in the Treatment Landscape

The most important shift in the myasthenia gravis treatment landscape is the transition from symptom control to disease-modifying immune modulation. Complement C5 inhibition and FcRn blockade have demonstrated clinically meaningful improvements in validated endpoints such as Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores, supporting more personalized treatment sequencing for generalized myasthenia gravis.

Healthcare systems are also shifting from episodic rescue care to proactive management of chronic autoimmune neuromuscular disease. Specialty infusion networks, subcutaneous and self-administration options, real-world evidence programs, and patient-reported outcome tracking are becoming competitive differentiators. At the same time, high-cost biologics are intensifying payer scrutiny, making comparative effectiveness, durability of response, relapse prevention, corticosteroid reduction, and quality-of-life evidence central to market access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant across the myasthenia gravis treatment value chain, particularly in earlier recognition, patient stratification, trial optimization, and pharmacovigilance. Machine learning applied to claims data, electronic health records, neurology notes, and laboratory patterns can help identify underdiagnosed patients and predict risk of exacerbation, while natural language processing can extract weakness patterns, dysphagia, diplopia, ventilatory support, and rescue therapy events from unstructured clinical documentation.

AI is also improving clinical development efficiency by supporting site selection, protocol feasibility, synthetic control exploration, patient-reported outcome analysis, and adverse-event signal detection. However, regulated clinical decision-making still requires physician oversight, transparent validation, bias testing, explainable models, and compliance with privacy frameworks such as HIPAA and GDPR. Leaders that combine AI with clinically curated datasets will be better positioned to generate evidence that clinicians, regulators, and payers trust.

Key Regional Insights

North America remains a leading region for myasthenia gravis treatment adoption due to specialty neurology infrastructure, early biologic approvals, mature payer systems, and strong clinical trial participation. The United States anchors demand through rapid uptake of complement inhibitors and FcRn inhibitors, while Canada emphasizes evidence-based reimbursement, provincial access pathways, and specialist-led treatment protocols for generalized myasthenia gravis.

Europe is characterized by EMA authorization, national health technology assessment, and increasing emphasis on cost-effectiveness, with Germany, France, Italy, Spain, and the United Kingdom shaping access models through clinical benefit assessment, pricing negotiation, and real-world evidence requirements. Asia-Pacific is expanding as Japan, China, Australia, South Korea, and India improve antibody testing, diagnosis, rare disease pathways, and specialist capacity. Latin America shows rising clinical need through Brazil and Mexico, but access varies between public and private channels. The Middle East, led by high-investment tertiary care systems, is strengthening access to advanced neurology therapies, while Africa continues to face constraints related to diagnostic availability, specialist density, reimbursement, and supply chain reliability.

Key Group Insights

The G7 accounts for a major portion of advanced myasthenia gravis treatment adoption because its members combine specialty care networks, regulatory maturity, clinical trial participation, and reimbursement capacity for rare and specialty neurology therapies. The European Union plays a central role through centralized medicine authorization and country-level pricing negotiations, while NATO markets overlap substantially with higher-income healthcare systems that fund advanced immunology and neuromuscular disease treatments.

BRICS countries represent a long-term growth engine for myasthenia gravis treatment access, led by China, India, and Brazil, where rising diagnosis rates, healthcare investment, and expanding specialty care are increasing treated patient visibility. ASEAN markets are improving access through specialist hospital networks and public-sector modernization, although reimbursement and diagnostic availability remain heterogeneous. GCC countries benefit from centralized purchasing, tertiary care investment, and national strategies for specialty medicine access, supporting adoption of advanced therapies for severe generalized myasthenia gravis.

Key Country Insights

The United States leads in clinical innovation and advanced therapy adoption, supported by FDA approvals, specialty pharmacies, neuromuscular centers, and real-world evidence generation. Canada follows a structured reimbursement approach, while Mexico and Brazil are growing through private-sector access, public specialty programs, and increasing neurologist awareness. The United Kingdom, Germany, France, Italy, and Spain are shaped by national assessment bodies that prioritize clinical benefit, budget impact, treatment sequencing, and real-world outcomes. Russia remains relevant in regional access planning but faces complexity linked to procurement, reimbursement, and geopolitical factors.

China, Japan, India, Australia, and South Korea are central to Asia-Pacific expansion in myasthenia gravis treatment. Japan has strong rare disease and neurology infrastructure, China is scaling biologic access through regulatory modernization and hospital-based specialty care, and India offers large unmet need with affordability and diagnostic constraints. Australia and South Korea combine specialist capacity with evidence-based reimbursement and high-quality tertiary care, supporting broader use of advanced therapies where clinical and payer criteria are met.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate sustained symptom control, reduced exacerbations, steroid-sparing effects, improved daily functioning, and lower rescue therapy dependence. Payers are increasingly asking whether premium biologics reduce hospitalizations, intensive care use, plasma exchange, intravenous immunoglobulin reliance, and long-term corticosteroid burden, so real-world evidence should be built into launch and lifecycle plans.

Organizations should also invest in antibody testing pathways, physician education, patient support services, and differentiated administration models, including infusion, subcutaneous, and self-administration options where approved. Strategic partnerships with neuromuscular centers, specialty pharmacies, patient registries, and data platforms can accelerate diagnosis and improve adherence. For emerging markets, tiered access strategies, local evidence generation, diagnostic capacity building, and health-system partnerships will be essential to responsible growth.

Research Methodology

This executive summary is informed by triangulation of public regulatory records, peer-reviewed neurology literature, clinical trial registries, treatment guidelines, health technology assessment outputs, and published evidence on approved therapeutic classes. Emphasis was placed on validated clinical endpoints, antibody-defined populations, mechanism-of-action differentiation, regional access dynamics, and observable shifts in care delivery.

The research approach applies secondary data review, market structure analysis, therapy-class mapping, regional comparison, and expert interpretation of commercialization factors. Data points were assessed for consistency across authoritative sources such as FDA, EMA, clinical guideline bodies, clinical trial publications, and health technology assessment reports. Forward-looking insights are framed as evidence-based interpretations of current treatment and access trends rather than unsupported forecasts.

Conclusion

Myasthenia gravis treatment is entering a more targeted and competitive era, with complement inhibitors and FcRn inhibitors redefining expectations for generalized disease management. Conventional therapy remains foundational, but the center of gravity is shifting toward precision immunology, validated outcome measurement, individualized sequencing, and patient-centered care models.

Success in the global myasthenia gravis treatment landscape will depend on more than clinical efficacy. Leaders must demonstrate long-term value, streamline diagnosis, expand antibody testing, manage biologic access, and generate credible real-world evidence across diverse healthcare systems. Organizations that integrate science, data, affordability, and patient support will be best positioned as care for myasthenia gravis continues to evolve.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Myasthenia Gravis Treatment Market, by Treatment Class

• 7.1. Acetylcholinesterase Inhibitors
• 7.2. Immunosuppressants
  • 7.2.1. Corticosteroids
  • 7.2.2. Nonsteroidal Immunosuppressants
• 7.3. Intravenous Immunoglobulin
• 7.4. Monoclonal Antibodies
• 7.5. Plasma Exchange

8. Myasthenia Gravis Treatment Market, by Disease Type

• 8.1. Generalized Myasthenia Gravis
• 8.2. Ocular Myasthenia Gravis
• 8.3. Juvenile-Onset Myasthenia Gravis

9. Myasthenia Gravis Treatment Market, by Administration Route

• 9.1. Intravenous
• 9.2. Oral
• 9.3. Subcutaneous

10. Myasthenia Gravis Treatment Market, by Distribution Channel

• 10.1. Hospital Pharmacies
• 10.2. Online Pharmacies
• 10.3. Retail Pharmacies

11. Myasthenia Gravis Treatment Market, by End User

• 11.1. Clinics
• 11.2. Home Care
• 11.3. Hospitals

12. Myasthenia Gravis Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Myasthenia Gravis Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Myasthenia Gravis Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AstraZeneca PLC
• 16.2. argenx SE
• 16.3. UCB S.A.
• 16.4. Johnson & Johnson Services Inc.
• 16.5. Novartis AG
• 16.6. Grifols, S.A.
• 16.7. Takeda Pharmaceutical Company Limited
• 16.8. F. Hoffmann-La Roche Ltd.
• 16.9. Bausch Health Companies Inc.
• 16.10. Catalyst Pharmaceuticals, Inc.
• 16.11. Dr. Reddy's Laboratories Limited
• 16.12. Teva Pharmaceutical Industries Ltd.
• 16.13. Amgen Inc.
• 16.14. Arcellx, Inc.
• 16.15. Asahi Kasei Medical Co., Ltd.
• 16.16. Hikma Pharmaceuticals PLC
• 16.17. Immunovant Sciences GmbH
• 16.18. Merck KGaA
• 16.19. Regeneron Pharmaceuticals, Inc.
• 16.20. Terumo BCT, Inc.